Leerink Partners Downgrades Elevation Oncology (ELEV) to Market Perform
Tweet Send to a Friend
Leerink Partners analyst Andrew Berens downgraded Elevation Oncology (NASDAQ: ELEV) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
